Format
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 5

1.

Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.

Barthold SW, Hodzic E, Imai DM, Feng S, Yang X, Luft BJ.

Antimicrob Agents Chemother. 2010 Feb;54(2):643-51. doi: 10.1128/AAC.00788-09. Epub 2009 Dec 7.

2.

Immunological and molecular variability of OspA and OspC. Implications for Borrelia vaccine development.

Wilske B, Busch U, Fingerle V, Jauris-Heipke S, Preac Mursic V, Rössler D, Will G.

Infection. 1996 Mar-Apr;24(2):208-12. Review.

PMID:
8740124
3.

Antibiotic treatment of animals infected with Borrelia burgdorferi.

Wormser GP, Schwartz I.

Clin Microbiol Rev. 2009 Jul;22(3):387-95. doi: 10.1128/CMR.00004-09. Review.

4.

Critical analysis of treatment trials of rhesus macaques infected with Borrelia burgdorferi reveals important flaws in experimental design.

Wormser GP, Baker PJ, O'Connell S, Pachner AR, Schwartz I, Shapiro ED.

Vector Borne Zoonotic Dis. 2012 Jul;12(7):535-8. doi: 10.1089/vbz.2012.1012. Epub 2012 May 23. Review.

5.

Lyme Borreliosis: Is there a preexisting (natural) variation in antimicrobial susceptibility among Borrelia burgdorferi strains?

Hodzic E.

Bosn J Basic Med Sci. 2015 Jul 8;15(3):1-13. doi: 10.17305/bjbms.2015.594. Review.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk